期刊文献+

血PTH水平与尿毒症患者贫血及心血管疾病危险因素的相关性

Association between Parathyroid Hormone Level and Anemia, Risk Factors of Cardiovascular Disease in Uremic Patients
下载PDF
导出
摘要 目的:探讨甲状旁腺素(PTH)水平与尿毒症患者贫血及心血管疾病(CVD)危险因素的相关性。方法:收集91例首次就诊住院的尿毒症(CKD5期)患者,按血i PTH水平将患者分为甲状旁腺功能亢进组和非亢进组,比较两组的临床资料。结果:继发性甲状旁腺功能亢进(SHPT)的患病率为40.66%,与非亢进组相比,亢进组患者的平均年龄较轻,贫血较重,血钙、甘油三酯、空腹血糖和超敏C反应蛋白水平较低,血磷和血肌酐水平较高,残余肾功能较差,两组间有显著性差异(P<0.05)。相关性分析显示血i PTH水平与年龄、血红蛋白、肌酐清除率、甘油三酯、血钙水平呈负相关(P<0.05),与血肌酐和血磷水平呈正相关(P<0.05)。结论:低血钙、高血磷、低肾小球滤过率是SHPT发生的危险因素,SHPT会加剧肾性贫血,PTH与其他CVD危险因素间的相关性不明显,提示其通过直接作用于心血管系统而增加CVD风险。 Objective:To elevate the association between parathyroid hormone level and anemia , risk factors of cardiovascular disease in uremic patients. Methods: Medical records of 91 resident patients who were diagnosed as uremia (CKD 5 stage) for the first time were reviewed and classified into SHPT group and non-SHPT group according to the intact parathyroid hormone (iPTH) level. We then examined clinical features between the two groups. Results:The prevalence of SHPT was 40.66%. It revealed significantly younger age, lower level of hemoglobin, calcium, triglyceride, fasting blood glucose, hs-CRP and GFR, higher level of phosphorus and creatinine in SHPT group (P〈0.05). Correlation analysis showed that serum iPTH level was negatively correlated with age, hemoglobin, GFR, serum triglyceride and calcium level (P〈0.05), but positively correlated with serum creatinine and phosphorus level (P〈0.05). Conclusions: Hypocalcemia, hyperphosphatemia, lower GFR were risk factors of SHPT. Renal anemia was worsened by SHPT. The correlation between PTH and other risk factors of CVD were not obvious. It supported that PTH effected on the cardiovascular system directly to increase the risk of CVD.
出处 《岭南急诊医学杂志》 2015年第5期373-374,386,共3页 Lingnan Journal of Emergency Medicine
基金 广东省科技计划社会发展项目(2011B031800122)
关键词 尿毒症 继发性甲状旁腺功能亢进 贫血 心血管疾病危险因素 uremia secondary hyperparathyroidism anemia risk factors of cardiovascular disease
  • 相关文献

参考文献7

  • 1Nikodimopoulou M, Liakos S. Secondary hyperparathyro-idism and target organs in chronic kidney disease [ J ].Hippokratia, 2011,15(Suppl 1):33.
  • 2Sliem H, Tawfik G, Moustafa F, et al. Relationship ofassociated secondary hyperparathyroidism to serumfibroblast growth factor-23 in end stage renal disease :A case-control study [J]. Indian J Endocrinol Metab,2011,15(3):230.
  • 3Anderson JL, Vanwoerkom RC, Horne BD, et al.Parathyroid hormone, vitamin D, renal dysfunction,and cardiovascular disease: dependent or independentrisk factors [J]? Am Heart J, 2011, 162(2) : 331.
  • 4Buizert PJ, van Schoor NM,Simsek S,et al. PTH : anew target in arteriosclerosis? [J]. J Clin EndocrinolMetab, 2013,98(10):1583.
  • 5Komaba H, Taniguchi M, Wada A, et al.Parathyroidectomy and survival among Japanesehemodialysispatientswithsecondaryhyperparathyroidism [J]. Kidney Int, 2015 , 88(2):350.
  • 6Wannamethee SG, Welsh P, Papacosta 0, et al.Elevated parathyroid hormone, but not vitamin Ddeficiency, is associated with increased risk of heartfailure in older men with and without cardiovasculardisease [J]. Circ Heart Fail,2014,7(5):732.
  • 7周红梅,徐庆东,郑智华,阳晓,余学清.持续性非卧床腹膜透析患者继发性甲状旁腺功能亢进相关因素分析[J].中华肾脏病杂志,2012,28(12):933-936. 被引量:4

二级参考文献14

  • 1Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology, 2009, 55: 601-606.
  • 2Horl WHo The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant, 2004, 19 Suppl 5: V2-V8.
  • 3Peiris AN, YoussefD, Grant WB. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes? South MedJ, 2012, 105: 36-42.
  • 4Potthoff SA,Janus A, Hoch H, et a1. PTH - receptors regulate norepinephrine release in human heart and kidney. Regul Pept, 2011, 171: 35-42.
  • 5Triponez F, Dosseh D, Hazzan M, et a1. Results of systematic subtotal parathyroidectomy with thymectomy for tertiary hyperparathyroidism after renal transplantation in 70 patients. Ann Chir, 2006, 131: 203-210.
  • 6Billa V, Zhong A, BargmanJ, et a1. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Diallnt, 2000, 20: 315-321.
  • 7Suwan N. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.J Med Assoc Thai, 2011, 94 Suppl4: SIOI-SI05.
  • 8Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end - stage renal failure-an evolving disorder. Kidney Int, 1993,43: 436-442.
  • 9Sliem H, Tawfik G, Moustafa F, et al. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor - 23 in end stage renal disease: a case - control study. IndianJ Endocrinol Metab, 2011, 15: 105-109.
  • 10Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N EnglJ Med, 1993, 328: 171-175.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部